Lifecare, LIFE-ME

Bergensfirma utvikler spyttprøve som skal gi coronasvar på fem minutter
Et firma i Bergen har utviklet en spyttprøvetest for corona. Metoden testes nå ut i Tyskland og målet er å få testen på markedet før jul.


Et sveip med vattpinnen i munnen, pinnen legges ned i et rør som er koblet til en sensor som går videre til en boks fylt av elektronikk. Etter få minutter er svarer klart: Corona eller ikke corona.

– Hurtigtesten er basert på en helt ny type teknologi, sier administrerende direktør Joacim Holter i Lifecare til Bergens Tidende.

Skal prøve ut hurtigtest for corona

Firmaet har utviklet testen i samarbeid med det tyske selskapet Digital Diagnostics AG, som skal være ferdig med å teste metoden i oktober.

Holter ser en lang rekke fordeler med hurtigtesten fremfor vanlig testing:

– For den enkelte er munnavstryking langt mer behagelig enn vattpinne opp i bihulene. I tillegg er det en fordel å få raskt svar. Det er helsepersonell eller personer med opplæring som skal utføre testen.

Kjendiser hamstrer helseaksjer

– Man unngår ikke kø, men vi sparer alle laboratorieressursene, sier Holter, som antyder en pris på 60 dollar per test, cirka 550 kroner.

Det er mer enn dobbelt så mye som hver test koster kommunen i dag, men da kommer labanalyse på rundt 500 kroner i tillegg.

WISeKey selected by the German health tech company Digital Diagnostics AG to secure its digid cantisense™ SARS-CoV-2 test

WISeKey selected by the German health tech company Digital Diagnostics AG to
secure its digid cantisense™ SARS-CoV-2 test

WISeKey selected by the German health tech company Digital Diagnostics AG to
secure its digid cantisense™ SARS-CoV-2 test

Geneva – September 14, 2020 - WISeKey International Holding Ltd (“WISeKey”,
SIX: WIHN / Nasdaq: WKEY), a leading cybersecurity and IoT company was
selected by the German health tech company digid - Digital Diagnostics AG, to
secure its digid cantisense™ SARS-CoV-2 test.

WISeKey cybersecurity and Identity Management is used to digitally certify and
encrypt the data originated by a new type of sensor device from the German
health tech company Digital Diagnostics AG that can be used for immediate
tests for the new SARS coronavirus. The digid cantisense™ SARS-CoV-2
test becomes a pocket-sized laboratory and can be used in four steps anywhere
on site by general practitioners, paramedics and nursing staff without much
prior knowledge.

The new rapid test detects antigens of SARS CoV-2 directly. Compared to
previously known rapid tests, it reacts much better and leads to a clear
electronic “YES” or “NO” statement regarding the presence of the virus in the
test liquid. The results are available within five minutes; the time-consuming
transport of the samples to the laboratory is no longer necessary.

The new digital diagnostic platform enables the rapid testing of millions of
people and thus enables real-time monitoring of the spread of the disease
within the population. By connecting the digital sensor to a secure database,
new regional hotspots of the virus spread can be recognized in real time and
immediately contained.

Det bergensbaserte teknologiselskapet Lifecare forsker og utvikler en miniatyrisert sensor for korrekt og kontinuerlig overvåking av blodsukker for diabetikere. Selskapets patenterte teknologi anvendes blant annet som måleenhet for avlesning av forskjellige biomarkører.

I samarbeid med seks akademiske partnere i Italia, Frankrike og Tyskland har Lifecare etablert prosjektet «FORGETDIABETES», med den målsetning å utvikle en kunstig og hel-automatisert bukspyttkjertel for implantering i menneskets bukhule.

WISeKey closes $300,000 contract with arago to secure COVID-19 pandemic management, engaging in the 2nd deal in less than a month to actively fight the economic impact of COVID-19

FacebookLinkedInMore

WISeKey Cybersecurity for arago AI based risk management delivers end-2-end security for managing COVID-19 pandemic and building an ecosystem to minimize the global economic impact of any pandemic

Geneva – October 6, 2020 – WISeKey International Holding Ltd (“WISeKey”, SIX: WIHN / Nasdaq: WKEY), a leading cybersecurity and IoT company today announced the second contract (after a contract with DIGID was announcement early this month https://www.wisekey.com/press/wiseke...rs-cov-2-test/ ) supporting the global fight against COVID-19. The deal provides arago GmbH – a leading AI company heavily engaged in building pandemic management solutions on top of their existing knowledge automation platform HIRO™ – with the necessary end-2-end security for all data needed to proactively and safely manage and reduce COVID-19 infection risks on an individual basis. Using WISeKey’s cybersecurity and identity management system as part of arago’s risk management platform makes data received from testing stations, symptom checkers and other devices trustworthy and is the pre-condition for using this data to determine risk for an individual inside a managed environment. WISeKey Cybersecurity and IoT management will be gradually integrated in all arago COVID-19 projects with a visible pipeline exceeding $20 million for current COVID-19 projects only.

Investorer går i kø mot Lifecare-aksjen
Etter nyheten om at det Merkur-noterte helseselskapet Lifecare kan stå i startgropen for en revolusjon for en ny type diabetesbehandling har investorer kjøpt aksjer med begge hendene. Og aksjekursen har skutt i været.